What happens when patients stop taking GLP-1 drugs? New Cleveland Clinic study reveals real world insights
Thursday, March 12, 2026, CLEVELAND: As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings.
A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment.
In one of the largest real-world studies to date ...